JP2022552262A5 - - Google Patents
Info
- Publication number
- JP2022552262A5 JP2022552262A5 JP2022521243A JP2022521243A JP2022552262A5 JP 2022552262 A5 JP2022552262 A5 JP 2022552262A5 JP 2022521243 A JP2022521243 A JP 2022521243A JP 2022521243 A JP2022521243 A JP 2022521243A JP 2022552262 A5 JP2022552262 A5 JP 2022552262A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- approximately
- months
- mmol
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962911968P | 2019-10-07 | 2019-10-07 | |
| US62/911,968 | 2019-10-07 | ||
| PCT/US2020/054400 WO2021071835A1 (en) | 2019-10-07 | 2020-10-06 | Adeno-associated virus vector pharmaceutical composition and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022552262A JP2022552262A (ja) | 2022-12-15 |
| JP2022552262A5 true JP2022552262A5 (OSRAM) | 2023-10-17 |
Family
ID=73131798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022521243A Pending JP2022552262A (ja) | 2019-10-07 | 2020-10-06 | アデノ随伴ウイルスベクター医薬組成物および方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240108669A1 (OSRAM) |
| EP (1) | EP4041292A1 (OSRAM) |
| JP (1) | JP2022552262A (OSRAM) |
| KR (1) | KR20220081365A (OSRAM) |
| CN (3) | CN114728049A (OSRAM) |
| AR (1) | AR120171A1 (OSRAM) |
| AU (1) | AU2020362119A1 (OSRAM) |
| BR (1) | BR112022006718A2 (OSRAM) |
| CA (1) | CA3156984A1 (OSRAM) |
| IL (1) | IL291930A (OSRAM) |
| MX (1) | MX2022004146A (OSRAM) |
| TW (2) | TW202525312A (OSRAM) |
| WO (1) | WO2021071835A1 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020012336A2 (pt) | 2017-12-19 | 2021-03-30 | Akouos, Inc. | Administração de anticorpos terapêuticos mediada por aav para o ouvido interno |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| MX2023006471A (es) * | 2020-12-18 | 2023-08-11 | Sangamo Therapeutics Inc | Composiciones farmaceuticas mejoradas que contienen vector viral adenoasociado. |
| JP2025509566A (ja) * | 2022-03-14 | 2025-04-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａａｖ医薬製品の凍結乾燥製剤 |
| TW202404651A (zh) * | 2022-04-06 | 2024-02-01 | 美商銳進科斯生物股份有限公司 | 用於脈絡膜上投與之調配物諸如形成聚集體之調配物 |
| EP4593955A1 (en) | 2022-09-30 | 2025-08-06 | RegenxBio Inc. | Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab |
| CN115554418B (zh) * | 2022-11-22 | 2023-04-14 | 四川至善唯新生物科技有限公司 | 一种重组腺相关病毒载体的药物组合物及其用途 |
| CN115869425B (zh) * | 2022-12-12 | 2024-08-20 | 北京生物制品研究所有限责任公司 | 一种aav眼用注射液及其制备方法和应用 |
| IL321632A (en) * | 2022-12-23 | 2025-08-01 | Spark Therapeutics Inc | Adeno-associated virus formulations |
| WO2024220966A1 (en) * | 2023-04-21 | 2024-10-24 | The Regents Of The University Of California | Novel glycan compounds for age-related macular degeneration |
| AU2024271004A1 (en) | 2023-05-16 | 2026-01-15 | Regenxbio Inc. | Vectorized anti-complement antibodies and administration thereof |
| TW202508610A (zh) * | 2023-08-23 | 2025-03-01 | 大陸商上海瑞宏迪醫藥有限公司 | 醫藥組成物及其用途 |
| CN119015447A (zh) * | 2023-09-01 | 2024-11-26 | 康霖生物科技（杭州）有限公司 | 一种缓冲系统及其相应液体制剂及其用途 |
| CN119769462A (zh) * | 2023-10-07 | 2025-04-08 | 陈国韬 | 一种非器质性（心理性）勃起功能障碍大鼠模型的构建方法 |
| WO2025113676A1 (en) * | 2023-11-29 | 2025-06-05 | Neuexcell Therapeutics (Suzhou) Co., Ltd. | Compositions and methods for treating stroke in primates |
| WO2025217230A1 (en) | 2024-04-08 | 2025-10-16 | Regenxbio Inc. | Vectorized anti-complement antibodies and complement agents and administration thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1978095A1 (en) | 1993-02-12 | 2008-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptor proteins for controlling signal transduction and ligands binding thereto |
| ATE544776T1 (de) | 1994-12-29 | 2012-02-15 | Massachusetts Inst Technology | Chimäre dna-bindeproteine |
| WO1996041865A1 (en) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamcycin-based regulation of biological events |
| AU9036198A (en) | 1997-08-26 | 1999-03-16 | Ariad Gene Therapeutics, Inc. | Fusion proteins comprising a dimerization, trimerization or tetramerization domain and an additional heterologous transcription activation, transcription repression, dna binding or ligand binding domain |
| EP1003886A1 (en) | 1997-08-27 | 2000-05-31 | Ariad Gene Therapeutics, Inc. | Chimeric transcriptional activators and compositions and uses related thereto |
| CA2318402A1 (en) | 1998-01-15 | 1999-07-22 | Ariad Gene Therapeutics, Inc. | Regulation of biological events using multimeric chimeric proteins |
| EP1053241A1 (en) | 1998-02-13 | 2000-11-22 | President And Fellows Of Harvard College | Novel dimerizing agents, their production and use |
| EP2369002A1 (en) | 1999-08-09 | 2011-09-28 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs |
| US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
| SG10202108118RA (en) | 2001-11-13 | 2021-08-30 | Univ Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
| ES2975413T3 (es) | 2001-12-17 | 2024-07-05 | Univ Pennsylvania | Secuencias de serotipo 8 de virus adenoasociado (AAV), vectores que las contienen y usos de las mismas |
| HUE054805T2 (hu) | 2003-09-30 | 2021-09-28 | Univ Pennsylvania | Adeno-asszociált vírus (AAV) kládok, szekvenciák, az azokat tartalmazó vektorok és alkalmazásaik |
| BRPI0511764B8 (pt) | 2004-06-01 | 2021-05-25 | Avigen Inc | método de prevenção de agregação de vírions de vírus adeno-associado recombinante (raav) em uma preparação purificada de virions raav |
| EP3085389A1 (en) | 2005-04-07 | 2016-10-26 | The Trustees Of The University Of Pennsylvania | Method of increasing the function of an aav vector |
| WO2006132118A1 (ja) | 2005-06-09 | 2006-12-14 | Matsushita Electric Industrial Co., Ltd. | 振幅誤差補償装置及び直交度誤差補償装置 |
| WO2010138263A2 (en) | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| US8628966B2 (en) | 2010-04-30 | 2014-01-14 | City Of Hope | CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer |
| CN107828820B (zh) | 2010-10-27 | 2022-06-07 | 学校法人自治医科大学 | 用于向神经系统细胞导入基因的腺相关病毒粒子 |
| US9409953B2 (en) | 2011-02-10 | 2016-08-09 | The University Of North Carolina At Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
| CN107012171B (zh) | 2011-04-22 | 2021-07-13 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
| EP3147295B2 (en) | 2011-08-24 | 2023-11-22 | The Board of Trustees of the Leland Stanford Junior University | New avv capsid proteins for nucleic acid transfer |
| EP3470523A1 (en) | 2012-05-09 | 2019-04-17 | Oregon Health & Science University | Adeno associated virus plasmids and vectors |
| CA2905952A1 (en) | 2013-03-13 | 2014-10-02 | The Children's Hospital Of Philadelphia | Adeno-associated virus vectors and methods of use thereof |
| EP3564379A1 (en) | 2013-09-13 | 2019-11-06 | California Institute of Technology | Selective recovery |
| NZ718926A (en) | 2013-10-11 | 2021-12-24 | Massachusetts Eye & Ear Infirmary | Methods of predicting ancestral virus sequences and uses thereof |
| US10746742B2 (en) | 2014-04-25 | 2020-08-18 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
| US10064752B2 (en) | 2014-09-11 | 2018-09-04 | Orbit Biomedical Limited | Motorized suprachoroidal injection of therapeutic agent |
| WO2017180936A1 (en) | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| SG11201808440YA (en) | 2016-04-15 | 2018-10-30 | Regenxbio Inc | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
| DK3472317T3 (da) * | 2016-06-16 | 2022-05-23 | Adverum Biotechnologies Inc | Sammensætninger og fremgangsmåder til reduktion af okulær vaskularisation |
| PT3534922T (pt) * | 2016-11-04 | 2024-06-07 | Takeda Pharmaceuticals Co | Formulações de vírus adenoassociado |
| TWI832036B (zh) * | 2017-08-03 | 2024-02-11 | 美商航海家醫療公司 | 用於aav之遞送之組合物及方法 |
| CA3076905A1 (en) | 2017-09-27 | 2019-04-04 | The Johns Hopkins University | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
| IL327339A (en) * | 2018-11-14 | 2026-05-01 | Regenxbio Inc | Gene therapy for neural ceroid lipofuscinosis |
-
2020
- 2020-10-06 CN CN202080079668.3A patent/CN114728049A/zh active Pending
- 2020-10-06 US US17/766,941 patent/US20240108669A1/en active Pending
- 2020-10-06 JP JP2022521243A patent/JP2022552262A/ja active Pending
- 2020-10-06 MX MX2022004146A patent/MX2022004146A/es unknown
- 2020-10-06 KR KR1020227015158A patent/KR20220081365A/ko active Pending
- 2020-10-06 EP EP20801425.8A patent/EP4041292A1/en active Pending
- 2020-10-06 CN CN202610171188.9A patent/CN122005864A/zh active Pending
- 2020-10-06 IL IL291930A patent/IL291930A/en unknown
- 2020-10-06 BR BR112022006718A patent/BR112022006718A2/pt unknown
- 2020-10-06 WO PCT/US2020/054400 patent/WO2021071835A1/en not_active Ceased
- 2020-10-06 AU AU2020362119A patent/AU2020362119A1/en active Pending
- 2020-10-06 CA CA3156984A patent/CA3156984A1/en active Pending
- 2020-10-06 CN CN202610160081.4A patent/CN122005863A/zh active Pending
- 2020-10-07 AR ARP200102778A patent/AR120171A1/es unknown
- 2020-10-07 TW TW114110012A patent/TW202525312A/zh unknown
- 2020-10-07 TW TW109134835A patent/TWI879814B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7740842B2 (en) | Stable liquid formulations of antibodies | |
| JP2024178197A (ja) | 液体医薬組成物 | |
| AU2013255413C1 (en) | Pharmaceutical formulations of TNF-alpha antibodies | |
| CN102946861B (zh) | 浓缩蛋白制剂及其用途 | |
| CN1293916C (zh) | 稳定的胰岛素制剂 | |
| JP2022153418A5 (OSRAM) | ||
| JP2024016207A5 (OSRAM) | ||
| JP2021516671A5 (OSRAM) | ||
| JP2021504372A5 (OSRAM) | ||
| JP7089121B2 (ja) | 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤 | |
| AU2016280555A1 (en) | Anti-CGRP antibody formulation | |
| JP2022545967A5 (OSRAM) | ||
| CN104936607A (zh) | 稳定的TNFR:Fc融合蛋白药物组合物 | |
| WO2019020777A1 (en) | LIQUID FORMULATION OF A VEGF ANTAGONIST | |
| WO2023011502A1 (zh) | 含有抗il-4r抗体的稳定制剂 | |
| CN116056688A (zh) | 眼用液体组合物 | |
| CN107205925A (zh) | 液体药物组合物 | |
| CN118056572A (zh) | 含有抗il-17抗体的稳定制剂 | |
| JP6852049B2 (ja) | 改善された安定性を有するエタネルセプト組成物 | |
| WO2025177156A1 (en) | Stable ophthalmic pharmaceutical formulation of aflibercept | |
| AU2006202688B2 (en) | Stable liquid formulations of antibodies | |
| AU2002321055A1 (en) | Stable liquid formulations of antibodies | |
| OA17126A (en) | Pharmaceutical formulations of TNF-alpha antibodies | |
| HK1207316B (zh) | 抗催乳素受体抗体制剂 |